Tags

Type your tag names separated by a space and hit enter

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.
Emerg Microbes Infect. 2021 Dec; 10(1):629-637.EM

Abstract

COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.

Authors+Show Affiliations

National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.National Institutes for Food and Drug Control, Beijing, People's Republic of China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33691606

Citation

He, Qian, et al. "Heterologous Prime-boost: Breaking the Protective Immune Response Bottleneck of COVID-19 Vaccine Candidates." Emerging Microbes & Infections, vol. 10, no. 1, 2021, pp. 629-637.
He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629-637.
He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021). Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerging Microbes & Infections, 10(1), 629-637. https://doi.org/10.1080/22221751.2021.1902245
He Q, et al. Heterologous Prime-boost: Breaking the Protective Immune Response Bottleneck of COVID-19 Vaccine Candidates. Emerg Microbes Infect. 2021;10(1):629-637. PubMed PMID: 33691606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. AU - He,Qian, AU - Mao,Qunying, AU - An,Chaoqiang, AU - Zhang,Jialu, AU - Gao,Fan, AU - Bian,Lianlian, AU - Li,Changgui, AU - Liang,Zhenglun, AU - Xu,Miao, AU - Wang,Junzhi, PY - 2021/3/12/pubmed PY - 2021/4/7/medline PY - 2021/3/11/entrez KW - COVID-19 vaccine KW - Heterologous prime-boost KW - T cell response KW - neutralizing antibody KW - th1/th2 balance SP - 629 EP - 637 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 10 IS - 1 N2 - COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/33691606/Heterologous_prime_boost:_breaking_the_protective_immune_response_bottleneck_of_COVID_19_vaccine_candidates_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1902245 DB - PRIME DP - Unbound Medicine ER -